Archives — September 2013 back to current month (11)
With more than 25 years of experience in the biotech market, John McCamant, editor of the Medical Technology Stock Letter, understands how the seasons of the investment cycle can influence a company's value. But he sticks to the fundamentals: After all, a great pipeline and competent management can propel a biotech upward through blustery weather as well as blue sky. Find out how four companies fit his philosophy in this interview with The Life Sciences Report.
"The analysis of the top 20 sectors of the worldwide medical device market reveals that the IVD sector is expanding at a CAGR of 5.1%, outpacing the overall medtech market growth rate of 4.5%."
It's important to take the emotion out of investing. Keay Nakae, senior research analyst with Ascendiant Capital Markets, looks at micro- and small-cap biotech stocks from an engineer's perspective: It's all about the data. In this interview with The Life Sciences Report, Nakae reports on four companies with upcoming catalysts that potentially position them for significant growth—and the ability to grab investors' attention.
The Next Step in Killing Cancer (09/16/2013)
"After several years of trial and error, Olson and his team at the privately owned Seattle biotech firm Blaze Bioscience, have created something called 'tumor paint.' And the solution has come from the most unlikely of places. . .Scorpion venom."
Ladenburg Thalmann & Co. Inc.'s Jeff Cohen regularly explores the frontiers of regenerative and medical technology looking for solid investment opportunities. In this interview with The Life Sciences Report, Cohen reveals promising finds in one of the world's fastest-growing business sectors. From robotics to skin grafts, Cohen knows his science and his market.
As science director for Griffin Securities, Keith Markey knows his way around the advanced technologies of the most promising research in biotech. In this interview with The Life Sciences Report, Markey explains the science behind new developments in the antibiotic, diabetic and dermatological fields, highlighting ground-floor investment opportunities that investors will not want to miss.
"The Patient Protection and Affordable Care Act (PPACA), particularly the medical device excise tax, has taken a heavy toll on the medtech sector, hurting pricing decisions of the companies and subjecting them to tremendous margin pressure."
Neuroscience is about as complex as it gets. The central nervous system contains the brain and spinal cord, where hundreds of billions of neurons are located—and that doesn't include the peripheral nervous system. Casey Lynch, managing director of NeuroInsights, works to make sense of both the disease processes affecting the nervous system and potential therapies that could help patients and enrich investors. In this interview with The Life Sciences Report, Lynch brings some clarity to the complexity, and speaks frankly about the wild goose that some Alzheimer's disease investigators have been chasing.
It's that time again. From Labor Day through the New Year, analysts jet off to conferences across the U.S. and Europe to hear data they've been waiting on for years. Michael King, managing director and senior biotechnology analyst at JMP Securities, has been at this game for almost two decades, and he has a firm grip on how data releases about molecules and their targets will affect the biotech stocks in his coverage. In this interview with The Life Sciences Report, King also names four growth companies making important advances in hematologic cancers. Just in time.
"The FDA's new development path is specifically designed for experimental agents that produce large and unprecedented treatment effects in early clinical trials. If a drug is designated a breakthrough therapy, the FDA says it will expedite the development and review of the drug."
|"DRRX has received an upfront payment of $12.5 million, and is also eligible for $5 million in the event of FDA approval for Indivior's RBP-7000."|
|"INO announced the publication of two preclinical studies of the company's plasmid DNA-encoded monoclonal antibody constructs in treating cancer and preventing infection from a pneumonia-causing bacteria."|
|RP's Phase 1/2a trial for tendon repair in chronic Achilles tendinosis met its goal and established a complete safety profile at six months that showed no serious adverse events."|